Inherited cardiac diseases, pluripotent stem cells and genome editing combined - the past, present and future.
Research on mechanisms underlying monogenic cardiac diseases such as primary arrhythmias and cardiomyopathies has until recently been hampered by inherent limitations of heterologous cell systems, where mutant genes are expressed in non-cardiac cells, and physiological differences between humans and experimental animals. Human induced pluripotent stem cells (hiPSCs) have proven a game-changer by providing new opportunities for studying the disease in the specific cell type affected, namely the cardiomyocyte. hiPSCs are particularly valuable because not only can they be differentiated into unlimited numbers of these cells, but they also genetically match the individual from whom they were derived. The decade following their discovery showed the potential of hiPSCs for advancing our understanding of cardiovascular diseases, with key pathophysiological features of the patient being reflected in their corresponding hiPSC-derived cardiomyocytes (the past). Now, recent advances in genome editing for repairing or introducing genetic mutations efficiently has enabled the disease etiology and pathogenesis of a particular genotype to be investigated (the present). Finally, we are beginning to witness the promise of hiPSC in personalized therapies for individual patients, as well as their application in identifying genetic variants responsible for or modifying the disease phenotype (the future). In this review we discuss how hiPSCs could contribute to improving the diagnosis, prognosis and treatment of an individual with a suspected genetic cardiac disease, thereby developing better risk stratification and clinical management strategies for these potentially lethal but treatable disorders. © AlphaMed Press 2019 SIGNIFICANCE STATEMENT: A key feature of monogenic cardiac diseases is their variable expressivity and incomplete penetrance. Genetics plays a major role in this through both the primary genetic mutation and the presence of additional genetic variants that modify the disease outcome. Genome sequencing of individuals, as well as ongoing genome-wide association studies, identify many possible variants that could be involved but need to be validated. Here we discuss how the combination of human pluripotent stem cells and genome editing offers a potential link in not only investigating the pathogenicity of these primary genetic mutations, but also in determining the contribution of modifying variants. Understanding this should improve clinical decision-making and advance the field toward making precision medicine a reality.